|Dr. Lakhmir S. Chawla||Chief Medical Officer||529.43k||N/A||1971|
|Mr. Dennis M. Mulroy||Chief Financial Officer||N/A||N/A||1955|
|Mr. James M. Rolke||Chief Scientific Officer||N/A||N/A||1969|
|Sandra Vedrick||Sr. Director of Investor Relations & HR||N/A||N/A||N/A|
|Mr. Darryl Wellinghoff||Chief Commercial Officer||N/A||N/A||1969|
La Jolla Pharmaceutical Company, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for life-threatening diseases. The company offers GIAPREZA (angiotensin II), an injection for intravenous infusion indicated to increase blood pressure in adults with septic or other distributive shock. It is also developing LJPC-0118 for the treatment of severe malaria; and LJPC-401 (synthetic human hepcidin), a clinical-stage investigational product to treat conditions characterized by iron overload, including hereditary hemochromatosis, beta thalassemia, sickle cell disease, myelodysplastic syndrome, and polycythemia vera. The company was founded in 1989 and is headquartered in San Diego, California.
La Jolla Pharmaceutical Company’s ISS Governance QualityScore as of February 3, 2020 is 5. The pillar scores are Audit: 2; Board: 6; Shareholder Rights: 3; Compensation: 9.